Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Prostate Cancer Prostatic Dis. 2007;10(4):331-9. Epub 2007 May 1.

Inhibition of Akt pathways in the treatment of prostate cancer.

Author information

  • 1Department of Urology, University of California at Davis, Sacramento, CA, USA.

Abstract

Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.

PMID:
17471291
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk